By Elana Gotkine HealthDay ReporterMONDAY, Oct. 30, 2023 -- For critically ill patients undergoing mechanical ventilation for at least three days, a three-day course of inhaled amikacin reduces the subsequent burden of ventilatory-associated pneumonia, according to a study published online Oct. 25 in the New England Journal of Medicine.

根据Elana Gotkine HealthDay ReporterMONDAY，2023年10月30日-对于接受机械通气至少三天的重症患者，根据一项研究发表，为期三天的吸入阿米卡星疗程可减轻随后的通气相关性肺炎负担在线10月25日在新英格兰医学杂志上。

The study was published to coincide with the annual congress of the European Society of Intensive Care Medicine, held from Oct. 21 to 25 in Milan.Stephan Ehrmann, M.D., Ph.D., from the Centre Hospitalier Régional Universitaire de Tours in France, and colleagues conducted a multicenter superiority trial involving critically ill adults who had been undergoing invasive mechanical ventilation for at least 72 hours to receive inhaled amikacin once daily or placebo for three days (417 and 430 patients, respectively).

该研究与10月21日至25日在米兰举行的欧洲重症监护医学会年会同时发表。Stephan Ehrmann，医学博士，博士，来自法国图尔大学中心医院，及其同事进行了一项多中心优势试验，涉及接受有创机械通气至少72小时的重症患者，每天一次或安慰剂接受吸入阿米卡星治疗3天（分别为417例和430例）。

Overall, 337 and 355 patients (81 and 82 percent) received all three daily nebulizations in the amikacin and placebo groups, respectively.The researchers found that ventilator-associated pneumonia developed at day 28 in 15 percent of patients in the amikacin group and 22 percent in the placebo group (difference in restricted mean survival time to ventilator-associated pneumonia, 1.5 days).

总体而言，337例和355例患者（81%和82%）分别在阿米卡星组和安慰剂组接受了所有三次每日雾化治疗。研究人员发现，丁胺卡那霉素组15%的患者在第28天出现呼吸机相关性肺炎，安慰剂组为22%（呼吸机相关性肺炎的平均生存时间限制为1.5天）。

In 18 and 26 percent of the patients in the amikacin and placebo groups, respectively, an infection-related ventilator-associated complication occurred (hazard ratio, 0.66). Overall, 1.7 percent of patients in the amikacin group and 0.9 percent in the placebo group had trial-related serious adverse effects.'In this large multicenter trial, a three-day course of amikacin reduced the burden of ventilator-associated pneumonia by day 28 as compared with placebo,' the authors write.

阿米卡星组和安慰剂组分别有18%和26%的患者发生感染相关的呼吸机相关并发症（危险比为0.66）。总体而言，阿米卡星组为1.7%，安慰剂组为0.9%有试验相关的严重不良反应“在这项大型多中心试验中，与安慰剂相比，阿米卡星为期三天的疗程在第28天减少了呼吸机相关性肺炎的负担，“作者写道。

'Results were consistent with regard to ventilator-associated event.

'结果与呼吸机相关事件一致。